TNFSF11 and osteoporosis: The binding of RANKL to RANK receptors present in osteoclast precursors is critical for their differentiation toward mature osteoclasts, as revealed by the profound inhibition of bone resorption induced by anti-RANKL antibodies, which are a well-established therapy for osteoporosis [7].